Newly developed retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is sparking considerable buzz within the healthcare community. Initial clinical trials have revealed impressive reductions in overall mass and gains in physiological markers for patients with obesity . Researchers believe this unique approach